CD276 and neuroblastoma: SCAN-ACT identified 174 monospecific CAR-T targets in GBM (Fig. 7B, Additional file 1:Table S35), including several established GBM CAR-T targets such as CD276 [202], EGFR, IL13RA2 [203], ROBO1 [204], as well as targets studied in different diseases like GPC2 in neuroblastoma [205], IL11RA in osteosarcoma [206], or DLL3 in lung cancer [207].